An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Tc 99m tilmanocept (Primary) ; Tc 99m sulfur colloid
- Indications Liver metastases
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 12 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2018.
- 08 May 2018 Planned number of patients changed from 11 to 12.
- 08 May 2018 Planned End Date changed from 1 Jul 2018 to 1 Sep 2018.